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Significance
============

SARS-CoV-2 is the virus responsible for the coronavirus disease 2019 (COVID-19) pandemic. Potent, broad-spectrum α-ketoamide inhibitors of the main protease (M ^pro^ ) of betacoronaviruses and alphacoronaviruses were recently reported by Hilgenfeld and co-workers ( *J. Med. Chem.* **2020** , DOI: 10.1021/acs.jmedchem.9b01828). X-ray crystallography and structure-based design led to the discovery of submicromolar α-ketoamide inhibitor **13b** , which has now been developed specifically against SARS-CoV-2 M ^pro^ to shut down the processing of polyproteins translated from viral RNA.

Comment
=======

Starting from commercially available ( *R* )-2-amino-3-cyclopropylpropanoic acid, Boc-protected pyridone **D** is synthesized in four steps. γ-Lactam  **B** , a proxy for glutamine, is made using an asymmetric dianionic cyanomethylation of *N* -Boc- [l]{.smallcaps} -(+)-glutamic acid dimethyl ester (Q. Tian et al. *Tetrahedron Lett.* **2001** , *42* , 6807) and is coupled to the hydrolysis product of **D** . Five additional transformations yield **13b** , which inhibits SARS-CoV-2 M ^pro^ with IC ~50~ = 0.67±0.18 μM and displays promising lung tropism and inhalation tolerance in mice.
